Check for updates

OPEN ACCESS

EDITED BY Hua You, Nanjing Medical University, China

REVIEWED BY Juan Jesús García-Iglesias, University of Huelva, Spain Honglan Zhu, Peking University People's Hospital, China

*CORRESPONDENCE Xiaoqian Zhang 🖂 2187zhang@gmail.com

SPECIALTY SECTION This article was submitted to Public Mental Health, a section of the journal Frontiers in Public Health

RECEIVED 22 November 2022 ACCEPTED 23 January 2023 PUBLISHED 15 February 2023

CITATION

Zhang X, Wang C, Zuo X, Aertgeerts B, Buntinx F, Li T and Vermandere M (2023) Study characteristical and regional influences on postpartum depression before vs. during the COVID-19 pandemic: A systematic review and meta-analysis. *Front. Public Health* 11:1102618. doi: 10.3389/fpubh.2023.1102618

COPYRIGHT

© 2023 Zhang, Wang, Zuo, Aertgeerts, Buntinx, Li and Vermandere. This is an open-access article distributed under the terms of the **Creative Commons Attribution License (CC BY)**. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Study characteristical and regional influences on postpartum depression before vs. during the COVID-19 pandemic: A systematic review and meta-analysis

Xiaoqian Zhang^{1,2*}, Chun Wang³, Xiaoli Zuo², Bert Aertgeerts¹, Frank Buntinx¹, Tang Li⁴ and Mieke Vermandere¹

¹Department of Public Health and Primary Care, Academic Center for General Practice, Katholieke Universiteit Leuven, Leuven, Belgium, ²Department of Family Medicine, Qingdao United Family Hospital, Qingdao, China, ³Department of Obstetrics and Gynecology, Qingdao Municipal Hospital, Qingdao, China, ⁴Department of Pediatrics, Qingdao University Medical College, Qingdao, China

Background: While the public is under serious pressure from the coronavirus disease 2019 (COVID-19), the final impact and possible contributing factors to postpartum depression symptoms (PPDS) remain unknown. Therefore, a meta-analysis to investigate the association between PPDS and the COVID-19 pandemic was carried out by comparing the data between pre-pandemic and post-pandemic timeframes and exploring the influencing factors.

Methods: This systematic review was prospectively registered and recorded in a study protocol (Prospero CRD42022336820, http://www.crd.york.ac.uk/PROSPERO). A comprehensive search of PubMed, Embase, Web of Science, CINALH, Cochrane and Scopus was cmpleted on June 6, 2022. Studies that compared the prevalence of PPD before and during the COVID-19 pandemic period were included.

Results: Of 1766 citations identified, 22 studies were included with 15,098 participates before the COVID-19 pandemic and 11,836 participants during the COVID-19 pandemic. Overall, the analysis showed that the epidemic crisis was associated with an increased prevalence of PPDS (OR: 0.81 [0.68, 0.95], P = 0.009, $l^2 = 59\%$). Subgroup analysis was conducted according to the study characteristics and regions. Within the study characteristics classification, results showed an obvious increase in the prevalence of PPDS during the COVID-19 pandemic if PPDS cutoff was defined as Edinburgh postpartum depression score (EPDS) ≥13 points (OR: 0.72 [0.52, 0.98], P = 0.03, $l^2 = 67\%$) and an increased prevalence in follow-ups that happened after 2 weeks (> 2 weeks postpartum) (OR: 0.81 [0.68, 0.97], P = 0.02, $l^2 = 43\%$). Selected studies that were high-guality (OR: 0.79 [0.64, 0.97], P = 0.02, $l^2 = 56\%$) demonstrated an increased prevalence of PPDS during the COVID-19 pandemic period. Sorting by regional factors, studies conducted in Asia (OR: 0.81 [0.70, 0.93], P = 0.003, $l^2 = 0\%$) showed an increase of PPDS prevalence rates during the COVID-19 period, while studies conducted in Europe (OR: 0.82 [0.59, 1.13], P = 0.23, $l^2 = 71\%$) and North America (OR: 0.66 [0.42, 1.02], P = 0.06, $I^2 = 65\%$) showed no significant difference. All studies conducted in the developed (OR: 0.79 [0.64, 0.98], P = 0.03, $l^2 = 65\%$) and developing countries (OR: 0.81 [0.69, 0.94], P = 0.007, $I^2 = 0\%$) showed an increase of PPDS during the COVID-19 period.

Conclusions: The COVID-19 pandemic is associated with an increased prevalence of PPDS, especially after long-term follow-up and among the group with a high possibility of depression. The negative influence from the pandemic, causing more PPDS was significant in studies from Asia.

KEYWORDS

postpartum depression, depression, COVID-19, postpartum, influencing factors

1. Introduction

The Coronavirus disease 2019 (COVID-19) pandemic spread rapidly from Wuhan, China to the world and quickly developed into a global crisis (1). Confronted with the rapid increase in the number of infections and the uncertainty of the outcome, people in the whole world are facing varying degrees of psychological pressure. The fear of the COVID-19 infection and the strict isolation measures have produced a negative impact on the mental health of people (2, 3).

The term postpartum depression (PPD) refers to episodes of depression that usually appear within 4 weeks of delivery and can last for years (4). Postpartum women are more susceptible to clinical depression, marked by agitation, mood swings and sleep disorders (1, 5). Postpartum depression symptoms (PPDS) are one of the most common mental problems affecting 10–17% of postpartum individuals and causing significant morbidity and mortality (6–8). Suicide caused by postpartum mental problems accounts for about 20% of postpartum deaths (9). In addition, postpartum depression during this period can negatively influence the health and emotional development of newborns which can become a burden on both families and societies (10).

It is likely that those who already suffer from physical or mental health conditions, such as postpartum depression, will be most adversely affected by the current pandemic (11). Recently, numerous studies focused on the effect of the COVID-19 pandemic on PPDS, have produced conflicting results. Several studies demonstrated that the prevalence of PPDS is unchanged or even decreased during the COVID-19 pandemic (12-14), while others identified an increased prevalence (15-17). Yan et al. (18) included three studies in their meta-analysis and concluded that the prevalence of postpartum depression was 22%, while Shorey et al. (19) included five studies and demonstrated that the prevalence of postpartum depression was 17% during the COVID-19 period. Hessami et al. (20) evaluated the effect of the COVID-19 pandemic on the depression of women during pregnancy and the perinatal period through meta-analysis and found that the COVID-19 pandemic seems to have no significant influence on the diagnosis of depressive symptoms. Yet, only limited studies have compared the negative effect from the COVID-19 pandemic to postpartum women (21). Therefore, the goal of this systematic review and meta-analysis is to investigate the impact of the COVID-19 pandemic on the prevalence of PPDS by comparing the data from the pre-pandemic and post-pandemic timeframes, and exploring possible influencing factors from different subgroups of study characteristics and regions.

2. Methods

2.1. Protocol and registration

This systematic review was prospectively registered and recorded in a study protocol (Prospero CRD42022336820, http://www.crd. york.ac.uk/PROSPERO). This study was based on the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines (22) and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (23).

2.2. Eligibility criteria

Studies that reported the prevalence of PPDS during the postpartum period before and during the COVID-19 pandemic were included. Studies were eligible if they met the following criteria: (a) data were available during both pre- and post-pandemic timeframes and data for the postpartum period (b) utilized standardized and validated rating scales for measurement and (c) applied a clear cutoff for screening and defining PPDS. The time of the postpartum period was not limited. No restrictions were applied on the basis of the study setting, the study design, or the country.

Studies were excluded from this review if they met the following criteria: (a) not original articles such as commentaries, editorials, case reports, letters to editor, review studies, conference abstracts, etc.; (b) irrelevant studies or animal studies; (c) insufficient information was provided to calculate the prevalence of PPDS before and during the COVID-19 pandemic timeframe; (d) if a study included hypothetical or unquantified results (no supportive statistical evidence of analyzed outcome); (e) full-texts were inaccessible; or (f) data were presented in any language other than English.

2.3. Information sources

Six electronic databases (PubMed, Embase, Web of Science, CINALH, Cochrane and Scopus) were searched for related studies. Additional eligible articles were identified by manually searching cross-references of relevant articles (snowballing technique). The search was performed on June 6, 2022. We referred to the PICO-style approach and used combinations of the descriptors "postpartum/postnatal", "depression/mental health" and "COVID-19 pandemic" in English, applying all their synonyms and associated word variants, and searching titles, abstracts, keywords, and the Mesh Terms. The search was limited to 2019 onwards, since COVID-19 officially started in 2019. A detailed approach of the search strategy is described in Appendix A.

2.4. Study selection

Search data were exported to a citation program (Endnote X9), duplicates were discarded, and the final Endnote file was uploaded to the internet intelligent systematic review tool (Rayyan). The cataloging and organizing of the evidence were performed separately by the two primary reviewers (XQ.Z, C.W). Disagreements were resolved by group discussion or consultation with a third party (M.V, B.A, F.B). The final assessment was carried out together by one primary and three senior authors (XQ.Z, M.V, B.A, F.B).

2.5. Data extraction

For previously published data, only the most comprehensive articles have been included in this meta-analysis. The extracted data was as follows: first author name, publication year, study

Abbreviations: PPD, postpartum depression; PPDS, postpartum depression symptoms; COVID-19, coronavirus disease 2019; MOOSE, Observational Studies in Epidemiology guidelines; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses; EPDS, Edinburgh Postnatal Depression Scale; NOS, Newcastle-Ottawa Scale.

Country Study pop NOS Group Study period Sample Age References type Chrzan-Detkoś et al. (24) Poland \leq 1year Pre-post 5 Pre October 1-November 10, 2019 61 $31.04\pm3.70^*$ During February 20-March 30, 2020 78 $31.74\pm5.06^*$ Boekhorst et al. (25) Netherlands 8-10 weeks Pre-post 7 Pre January 7, 2019–March 1, 2020 250 $30.88 \pm 3.67^{*}$ During March 1-May 14, 2020 59 $30.75 \pm 3.64^{*}$ Eberhard-Gran et al (26) 2 weeks-13 months Norway Pre-post 6 Pre November 2008 to April 2010 4,662 NR 12 March 2020 to 12 April 2021 3,642 NR During Hiiragi et al. (27) 4-5 weeks 33 (29-37)# Japan Pre-post 6 Pre March 2019-June 2019 339 33 (29-37)# During March 2020–June 2020 279 Hui et al. (28) China Day 1 and 7 Pre-post 6 Pre January 1, 2019- January 4, 2020 3,432 $33.1\pm4.4^{\ast}$ During January 5, 2019- April 30, 2020 925 $33.1\pm4.6^{\ast}$ Kuipers et al. (14) Belgium <52 weeks Pre-post 7 Pre August 8, 2019-February 3, 2020 456 $30.53 \pm 4.06^{*}$ March 13, 2020-February 17, 2021 148 $30.44\pm3.7^*$ During Layton et al. (29) Canada ≤ 1 year Pre-post 6 Pre March, 2019- March, 2020 305 $32.94 \pm 5.17^{*}$ April- October, 2020 298 $31.74\pm4.78^*$ During Li et al. (30) China Week 6 Pre-post 7 Pre October-December, 2019 546 $29.36 \pm 3.5^*$ February-April, 2020 655 $30.49\pm3.7^*$ During $11.4 \pm 3.7^*$ months Loret de Mola et al. (31) Brazil Pre-post 5 Pre January 1-December 31, 2019 1.136 NR During May 11-July 20, 2020 1136 NR Mariño-Narvaez et al. Spain At most ≤ 1 month Pre-post 6 Pre September 1, 2019-March 1, 2020 82 $34.57\pm4.81^*$ (32)During April 1-July 1, 2020 75 $33.84 \pm 4.45^{*}$ Pariente et al. (13) Israel Day 2 6 Pre October 2016-April 2017 $28.3\pm5.0^{\ast}$ Pre-post 123 During March 18-April 29, 2020 223 $29.1\pm5.1^*$ Perez et al. (17) 3-8 weeks 8 2016-2019 $34.51 \pm 3.25^*$ Germany Pre-post Pre 97 During March 15-May 1, 2020 65 $36.02 \pm 4.55^{*}$ Madera et al. (33) Dhs 7 January, 2018-January, 2020 NR Italy Pre-post Pre 605 During May, 2020-October, 2020 295 NR Puertas-Gonzalez et al 7 March 2019-February 2020 $32.96 \pm 3.97^*$ Spain < 1 monthPre-post Pre 96 (34)April 1–July 1, 2020 $33.86 \pm 4.60^{*}$ During 116 Sade et al. (35) Dhs 7 NR Israel Pre-post Pre November, 2016-April, 2017 84 During March 19, 2020-May 26, 2020 279 NR Sudhinaraset et al. (36) Kenya ≤ 8 months Pre-post 6 Pre In 2019 1.014 NR During After March 16, 2020 1,072 NR Suzuki (12) Japan $\leq 1 \text{ month}$ Pre-post 5 Pre March 9-April 11, 2019 148 NR March 11-April 13, 2020 NR During 132 Vatcheva et al. (37) Belgium 3-6 months Pre-post 6 Pre January 1, 2017-December 31, 108 $30.0\pm5.2^*$ 2019 During April 1, 2020-March 31, 2021 34 $30.9\pm5.1^*$ Waschmann et al. (38) America < 3 months Pre-post 7 Pre January 1-June 1, 2019 557 $31.8 \pm 5.33^{*}$ During January 1-June 1, 2020 504 $31.4 \pm 5.48^{*}$ Yakupova et al. (39) Russia 7 $31.17 \pm 4.54^{*}$ < 14 months Pre-post Pre January-February 2020 611 During February-March 2021 1.645 $30.98 \pm 4.42^*$

TABLE 1 Characteristics of the included studies on postpartum depression (before COVID-19 vs. during COVID-19).

(Continued)

TABLE 1 (Continued)

References	Country	Study pop	Study type	NOS	Group	Study period	Sample size	Age
Zanardo et al. (15)	Italy	Day 2	Pre-post	7	Pre	March 8–May 3, 2019	101	$32.98\pm5.07^*$
					During	March 8–May 3, 2020	91	$33.73\pm5.01^*$
Zhang et al. (16)	Canada	6–10 weeks	Pre-post	8	Pre	March 1, 2019–February 29, 2020	285	$33.9\pm0.22^{\ast}$
					During	February 29, 2020–February 28, 2021	85	$34.6\pm0.45^*$

*Mean \pm SD, #median (interquartile range).

Study pop, Study population; Dhs, Duration of hospital stay; NOS, Newcastle-Ottawa scale; NR, not reported; Pre, Pre-COVID-19 pandemic; During: During-COVID-19 pandemic.

country, study population, study type, study quality, study period, and population age (Table 1). Data extraction was performed by the two primary reviewers. Discrepancies were resolved by discussion and consensus with a third party. Authors of the original publications were contacted in cases of missing data.

2.6. Risk of bias assessment

The two primary authors (XQ.Z/C.W) independently evaluated the risk of bias of the included studies using the Newcastle-Ottawa Scale (NOS) (40) to estimate the quality of the included studies. In the case of disagreement, a third party joined the discussion to determine a final decision. The final assessment was carried out together by three senior authors. Studies with a quality rating of five or greater were included in this meta-analysis. Studies with a score of seven or greater were classified as high-quality studies with the others being classified as moderate-quality studies (Table 1).

2.7. Statistical analysis and synthesis of results

The statistical software programs, Review Manager (RevMan 5.3) and Stata 12.0, were used for statistical analysis in this study. Chisquared statistics and I^2 tests were used to calculate heterogeneity (41) and the random effects model was used to deal with anticipated clinical heterogeneity. We conducted a sensitivity analysis to evaluate the effect of each included study by the comman of "metaninf" on Stata 12.0 (Supplementary Image 1). The Egger's test (42) and the Begg's test (43) were used to evaluate potential publication bias.

2.8. Subgroup analyses

Two predefined subgroup analyses and four exploratory subgroup analysis requested by the two primary reviewers (XQ.Z, C.W) were carried out based on the following classifications:

Study characteristics:

- A. Cut-off value of different assessment scales [predefined; cutoff value 9-11 and cut-off value ≥13 of Edinburgh Postnatal Depression Scale (EPDS)].
- B. Follow-up duration (predefined; within 2 weeks after delivery and more than 2 weeks after delivery).
- C. Different study quality (exploratory; high-quality studies and moderate-quality studies).

Regional subgroups

- D. Study continents (exploratory; Europe vs. Asia vs. North America).
- E. Different country types (exploratory; developed countries vs. developing countries).

3. Results

3.1. Description of studies

3.1.1. Study selection

The initial search provided a total of 1,766 articles of which 755 were deleted because of duplication. Another 1,011 articles were then excluded after screening titles and abstracts, and 122 items were evaluated for eligibility. Ultimately, 22 (12–17, 24–32, 34–39, 44) studies were selected for quantitative synthesis. Figure 1 demonstrated the detailed process of the literature search. The follow-up duration ranged from one day after delivery to 13 months after delivery in different studies.

3.1.2. Study characteristics

Table 1 outlines the detail characteristics of the included studies. A total of 22 studies with 11,836 participants during the COVID-19 pandemic timeframe and 15,098 before the COVID-19 pandemic timeframe were included in this meta-analysis. Among the 22 studies, 11 studies were conducted in Europe [two in Belgium (14, 37), two in Italy (15, 33), two in Spain (32, 34), one in Russia (39) and remaining four were in Germany (17), Norway (26), Poland (24) and Netherlands (25)], six studies were conducted in Asia [two in Japan (12, 27), two in China (28, 30) and two in Israel (13, 35)], three studies were conducted in North America [two in Canada (16, 29) and one in the United States (38)] and the remaining two studies were conducted in Brazil (31) and Kenya (36). Four of the included studies were conducted in developing countries (28, 30, 31, 36) and the remaining 18 studies were conducted in developed countries. Five of the included studies detected the mental health of women within 2 weeks postpartum (13, 15, 28, 33, 35) and the other 17 studies recorded the mental health of the women within a longer time after delivery. The study quality of 11 studies were high (14-17, 25, 30, 32, 33, 35, 38, 39) and the other 11 studies were moderate. Nine studies which used the EPDS scale chose a cut-off value of 9-11 (12, 17, 27, 28, 32, 34, 35, 38, 39), while another eight studies chose a cut-off value of ≥ 13 (14–16, 25, 29–31, 33). Three studies compared different cut-off values (9–11 and \geq 13) (13, 24, 37). Among the 22 studies, 20 studies assessed PPDS by using the standard EPDS



scale, while one study (36) assessed postpartum depression by using the World Health Organization's Maternal Tool and the other one used a short form of EPDS scale (EPDS-4) (26). The data of three studies were not quantitatively analyzed due to the fact that two study (26, 36) used a different measuring system, while the other study (37) only looked at mothers of extreme and early preterm infants. At this moment, 19 studies were included in the further meta-analysis (8, 12–17, 24, 25, 27–33, 35, 38, 39).

3.2. Risk of bias in included studies

All studies included in the meta-analysis used EPDS as a measuring scale and compared information from pre-pandemic and post-pandemic timeframes. The qualities of the eligible studies were evaluated based on the Newcastle-Ottawa Scale (NOS) assessment tool and studies with a quality assessment score above four (low quality = 0-3; moderate quality = 4-6; high quality = 7-9) were included in the review. Table 1 shows a summary of the quality assessment of all studies included in the meta-analysis using the NOS tool.

3.3. Data synthesis and statistical analysis

3.3.1. Overall analysis

Nineteen of the twenty-two selected studies reported PPDS using the standard EPDS scale during the pre-pandemic and post-pandemic timeframes. Furthermore, we conducted a sensitivity analysis and deleted one study (31) because of an apparent deviation

(Supplementary Image 1). In the end, only 18 studies were included in the final meta-analysis (12–17, 24, 25, 27–33, 35, 38, 39). Overall, the epidemic crisis is associated with an increased prevalence of PPDS (OR: 0.81 [0.68, 0.95], P = 0.009) though the high heterogeneity in the forest plot (I² = 53%) (Figure 2). We used Stata 12.0 software to examine the publication bias using Begg's funnel plots and no publication bias was discovered (Begg's test: P = 0.130; Egger's test: P = 0.325).

3.3.2. Subgroup analysis

3.3.2.1. Subgroup analysis in study characteristics 3.3.2.1.1. Subgroups with different cut-offs

Two cut-off points for EPDS were commonly used in the literature: ≥ 10 points was more suitable and sensitive for routine use in a primary setting for detecting PPDS, whereas ≥ 13 indicated that a likely case of PPDS of varying severity required an extended clinical examination (45). We conducted the subgroup analysis according to the different cut-off values of EPDS. As shown in Figure 3, women delivering during the COVID-19 pandemic had no significant increase in the prevalence of PPDS with the cut-off value of EPDS at 9–11 (OR: 0.90 [0.75, 1.08], P = 0.25, $I^2 = 51\%$) compared to women delivering before the pandemic. However, the prevalence of PPDS defined as EPDS ≥ 13 points (OR: 0.72 [0.52, 0.98], P = 0.03, $I^2 = 67\%$) showed an obvious increase during the COVID-19 pandemic (Figure 3).

3.3.2.1.2. Subgroups with different follow-up times

Postpartum depression will generally manifest within 2 weeks immediately after delivery with a peak incidence on the fifth day, and

dv or Subaroun							
idy of Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
ekhorst, Muskens et al. 2021	17	250	5	59	2.0%	0.79 [0.28, 2.23]	
rzan-Dętkoś, Walczak-Kozłowska et al.2021	48	61	65	78	2.7%	0.74 [0.31, 1.74]	
ragi, Obata et al.2021	34	339	38	279	5.5%	0.71 [0.43, 1.16]	
i, Ma et al.2021 (D1)	410	3432	133	925	9.3%	0.81 [0.65, 1.00]	
i, Ma et al.2021 (W1)	69	2970	23	802	5.6%	0.81 [0.50, 1.30]	
ipers, Bleijenbergh et al. 2022	106	456	29	148	5.8%	1.24 [0.78, 1.97]	
rton, Owais et al. 2021	217	305	240	298	6.9%	0.60 [0.41, 0.87]	
Wang et al. 2022	395	546	500	655	8.6%	0.81 [0.63, 1.05]	
riño-Narvaez, Puertas-Gonzalez et al. 2021	19	82	28	75	3.7%	0.51 [0.25, 1.01]	
riente, Wissotzky Broder et al.2020	38	123	37	223	5.2%	2.25 [1.34, 3.78]	
rez, Göbel et al. 2021	8	97	11	65	2.2%	0.44 [0.17, 1.17]	
tro Madera	43	605	35	295	5.7%	0.57 [0.36, 0.91]	
ertas-Gonzalez, Mariño-Narvaez et al. 2021	25	96	33	116	4.3%	0.89 [0.48, 1.63]	
de, Sheiner et al. 2020	21	84	81	279	4.8%	0.81 [0.47, 1.42]	
zuki 2020	22	148	19	132	3.9%	1.04 [0.53, 2.02]	
schmann, Rosen et al. 2022	94	557	91	504	7.8%	0.92 [0.67, 1.27]	
kupova, Suarez et al. 2021	279	611	722	1645	9.6%	1.07 [0.89, 1.29]	
nardo, Manghina et al.2020	12	101	26	91	3.3%	0.34 [0.16, 0.72]	
ang, Okeke et al. 2022	17	285	12	85	3.1%	0.39 [0.18, 0.84]	
al (95% CI)		11148		6754	100.0%	0.81 [0.68, 0.95]	•
al events	1874		2128				
terogeneity: Tau ² = 0.06; Chi ² = 43.48, df = 1	8 (P = 0.000	7); l² = 59	3%				
st for overall effect: Z = 2.61 (P = 0.009)							U.Z U.S 1 Z 5

Overall meta-analysis comparing the prevalence of PPDS before and during the COVID-19 pandemic.

	Pre-pano	lemic	Pande	nic		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
I.2.1 Cut-off value 9—11							
Chrzan-Dętkoś, Walczak-Kozłowska et al.2021	48	61	65	78	3.7%	0.74 [0.31, 1.74]	· · · · ·
Hiiragi, Obata et al.2021	34	339	38	279	8.2%	0.71 [0.43, 1.16]	
Hui, Ma et al.2021 (D1)	410	3432	133	925	15.9%	0.81 [0.65, 1.00]	
Hui, Ma et al.2021 (W1)	69	2970	23	802	8.5%	0.81 [0.50, 1.30]	
Mariño-Narvaez, Puertas-Gonzalez et al. 2021	19	82	28	75	5.2%	0.51 [0.25, 1.01]	
Pariente, Wissotzky Broder et al.2020	38	123	37	223	7.7%	2.25 [1.34, 3.78]	
Perez, Göbel et al. 2021	8	97	11	65	3.0%	0.44 [0.17, 1.17]	
Puertas-Gonzalez, Mariño-Narvaez et al. 2021	25	96	33	116	6.2%	0.89 [0.48, 1.63]	
Sade, Sheiner et al. 2020	21	84	81	279	7.0%	0.81 [0.47, 1.42]	
Suzuki 2020	22	148	19	132	5.5%	1.04 [0.53, 2.02]	
Naschmann, Rosen et al. 2022	94	557	91	504	12.5%	0.92 [0.67, 1.27]	
/akupova, Suarez et al. 2021	279	611	722	1645	16.6%	1.07 [0.89, 1.29]	
Subtotal (95% CI)		8600		5123	100.0%	0.90 [0.75, 1.08]	◆
Fotal events	1067		1281				
Heterogeneity: Tau ² = 0.04; Chi ² = 22.43, df = 11	(P = 0.02):	² = 51%					
Fest for overall effect: Z = 1.16 (P = 0.25)							
122 Cut officius 12							
1.2.2 Cut-on value 15	47	250	~	60	6.000	0.70 (0.00, 0.00)	
Boeknorst, Muskens et al. 2021	17	250	5	59	5.8%	0.79 [0.28, 2.23]	
Chrzan-Dętkos, Walczak-Kozłowska et al. 2021	40	61	58	/8	8.7%	0.66 [0.32, 1.37]	
Kulpers, Bieljenbergh et al. 2022	106	456	29	148	12.4%	1.24 [0.78, 1.97]	
Layton, Owais et al. 2021	217	305	240	298	13.6%	0.60 [0.41, 0.87]	and the second se
Li, Wang et al. 2022	395	546	500	655	15.2%	0.81 [0.63, 1.05]	a second and a second sec
Pariente, Wissotzky Broder et al. 2020	19	123	15	223	8.9%	2.53 [1.24, 5.19]	5 M M
Perez, Gobel et al. 2021	8	97	11	65	6.4%	0.44 [0.17, 1.17]	and the second sec
Pietro Madera	43	605	35	295	12.3%	0.57 [0.36, 0.91]	and the second sec
Zanardo, Manghina et al.2020	12	101	26	91	8.5%	0.34 [0.16, 0.72]	
Zhang, Okeke et al. 2022	17	285	12	85	8.2%	0.39 [0.18, 0.84]	
Subtotal (95% CI)		2829		1997	100.0%	0.72 [0.52, 0.98]	-
Fotal events	874		931				
Heterogeneity: Tau² = 0.15; Chi² = 27.16, df = 9 (F	e = 0.001); I	²= 67%					
Fest for overall effect: Z = 2.11 (P = 0.03)							

FIGURE 3

Subgroup analysis comparing the prevalence of PPDS before and during the COVID-19 pandemic according to the cut-off values of EPDS.

it can last year's (46, 47). Further subgroup analysis with different follow-up times was performed. Results showed that the prevalence of PPDS within 2 weeks of delivery showed no change before and during the COVID-19 period (OR: 0.81 [0.55, 1.19], P = 0.28, I^2

= 77%), while the prevalence of postpartum depression showed an obvious increase when detected after the first 2 weeks during the COVID-19 period (OR: 0.81 [0.68, 0.97], P = 0.02, $I^2 = 43\%$) (Figure 4).

Chucha an Cuchanaum	Pre-pant	Tatal	Fanue	Tetal	Mainht	MU Dendem 05% Cl	
Study of Subgroup	Events	Total	Events	lotal	weight	M-H, Random, 95% CI	M-H, Random, 95% CI
1.3.1 <> 2 Weeks							
Hui, Malet al. 2021 (D1)	410	3432	133	925	21.5%	0.81 [0.65, 1.00]	
Hui, Ma et al.2021 (VV1)	69	2970	23	802	17.1%	0.81 [0.50, 1.30]	
Pariente, Wissotzky Broder et al.2020	38	123	37	223	16.3%	2.25 [1.34, 3.78]	
Pietro Madera	43	605	35	295	17.2%	0.57 [0.36, 0.91]	
Sade, Sheiner et al. 2020	21	84	81	279	15.6%	0.81 [0.47, 1.42]	
Zanardo, Manghina et al.2020	12	101	26	91	12.3%	0.34 [0.16, 0.72]	
Subtotal (95% CI)		7315		2615	100.0%	0.81 [0.55, 1.19]	
Total events	593		335				
Heterogeneity: Tau ² = 0.17; Chi ² = 22.11, df = 5 (P = 0.0005)	; I ² = 779	‰				
Test for overall effect: Z = 1.08 (P = 0.28)							
1.3.2 > 2 Weeks							
Boekhorst, Muskens et al. 2021	17	250	5	59	2.4%	0.79 [0.28, 2.23]	
Chrzan-Detkoś, Walczak-Kozłowska et al.2021	48	61	65	78	3.4%	0.74 [0.31, 1.74]	
Hiiragi, Obata et al.2021	34	339	38	279	7.8%	0.71 [0.43, 1.16]	
Kuipers, Bleijenbergh et al. 2022	106	456	29	148	8.5%	1.24 [0.78, 1.97]	
Layton, Owais et al. 2021	217	305	240	298	10.6%	0.60 [0.41, 0.87]	.
Li, Wang et al. 2022	395	546	500	655	14.6%	0.81 [0.63, 1.05]	
Mariño-Narvaez, Puertas-Gonzalez et al. 2021	19	82	28	75	4.8%	0.51 (0.25, 1.01)	
Perez, Göbel et al. 2021	8	97	11	65	2.7%	0.44 [0.17, 1.17]	
Puertas-Gonzalez, Mariño-Narvaez et al. 2021	25	96	33	116	5.9%	0.89 [0.48, 1.63]	
Suzuki 2020	22	148	19	132	5.1%	1.04 [0.53, 2.02]	
Waschmann Rosen et al. 2022	94	557	91	504	12.6%	0.92/0.67 1.271	
Yakunova Suarez et al. 2021	279	611	722	1645	17 4%	1 07 [0 89 1 29]	
Zhang Okeke et al. 2022	17	285	12	85	4.0%	0 39 [0 18 0 84]	
Subtotal (95% CI)		3833		4139	100.0%	0.81 [0.68, 0.97]	•
Total events	1281	0000	1793		1001070	0101 [0100, 0101]	
Heterogeneity: $Tau^2 = 0.04$; $Chi^2 = 20.91$, $df = 12$	(P = 0.05)	1 ² = 43%	.155				
Test for overall effect: $7 = 2.35$ (P = 0.02)	(1 = 0.00),	- 4070					
restron overall ellect. 2 = 2.55 (r = 0.02)							
						-	
							0.2 0.5 1 2 5
							Higher Pandemic Higher Pre-pandemic
JURE 4							
i i i i i i i i i i i i i i i i i i i					0.01/	D 40 1 1	

3.3.2.1.3. Subgroups with different study quality

Statistical heterogeneity among different subgroups based on the study quality was evaluated by I^2 of Higgins (Figure 5). The results of the studies that were high-quality (OR: 0.79 [0.64, 0.97], P = 0.02, $I^2 = 56\%$) demonstrated an increased prevalence of PPDS during the COVID-19 pandemic period, while the prevalence of PPDS showed no significant increase in those studies with moderate quality.

3.3.2.2. Subgroup analysis in regions

3.3.2.2.1. Subgroups with different regions and country types

The studies conducted in the developed (OR: 0.79 [0.64, 0.98], P = 0.03, $I^2 = 65\%$) and developing countries (OR: 0.81 [0.69, 0.94], P = 0.007, $I^2 = 0\%$) showed an increase of PPDS during the COVID-19 period (Figure 6). Studies conducted in Asia (OR: 0.81 [0.70, 0.93], P = 0.003, $I^2 = 0\%$) showed an increase of PPDS during the COVID-19 period, while studies conducted in Europe (OR: 0.82 [0.59, 1.13], P = 0.23, $I^2 = 71\%$), and North America (OR: 0.66 [0.42, 1.02], P = 0.06, $I^2 = 65\%$) showed no significant difference. Further evidence is needed to examine potential differences in these subgroups (Figure 7).

4. Discussion

This meta-analysis compared the prevalence of PPDS by using data collected from both pre-pandemic and post-pandemic COVID-19 timeframes and explored the possible influence of study characteristics and regions. Results demonstrated that the COVID-19 pandemic is associated with an increased prevalence of PPDS, especially in the studies where a high risk of PPDS was defined as EPDS \geq 13 points and detected >2 weeks after delivery. Meanwhile,

Studies that were high-quality and conducted in Asia showed an increase of PPDS during the COVID-19.

4.1. Subgroups with different cut-offs

Diagnosis of postpartum depression requires a clinical interview where EPDS is used to indicate postpartum depressive symptoms. Different cut-offs were used with varying sensitivity and specificity (45). The results of the meta-analysis showed that a cut-off value of 10/11 had the greatest sensitivity and specificity for assessing the risk of a mild depressive disorder in perinatal women (48). A score of 9 or above is often used to indicate the likelihood of postpartum depression in Japanese women (49). In this study, we conducted a further subgroup analysis evaluating the different cut-off values of EPDS (Figure 3). Results demonstrated that women delivering during the COVID-19 pandemic had no significant increase in the prevalence of PPDS with the cut-off value of 9-11 compared to women delivering before the pandemic. However, the prevalence of PPDS defined as EPDS \geq 13 points had an obvious increase during the COVID-19 pandemic, suggesting that postpartum women who are more likely to suffer from a depressive illness might be more susceptible to the negative impacts of the COVID-19 pandemic.

4.2. Subgroups with different follow-up times

Postpartum depression, by definition, starts within 4 weeks postpartum and symptoms must persisting for at least 2 weeks

	Pre-pano	lemic	Pande	mic		Odds Ratio	Odds Ratio
tudy or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
5.1 High quality							
oekhorst, Muskens et al. 2021	17	250	5	59	3.4%	0.79 [0.28, 2.23]	
uipers, Bleijenbergh et al. 2022	106	456	29	148	10.2%	1.24 [0.78, 1.97]	
, Wang et al. 2022	395	546	500	655	15.2%	0.81 [0.63, 1.05]	
erez, Göbel et al. 2021	8	97	11	65	3.8%	0.44 [0.17, 1.17]	
ietro Madera	43	605	35	295	10.0%	0.57 [0.36, 0.91]	
uertas-Gonzalez, Mariño-Narvaez et al. 2021	25	96	33	116	7.5%	0.89 [0.48, 1.63]	
ade, Sheiner et al. 2020	21	84	81	279	8.3%	0.81 [0.47, 1.42]	
aschmann, Rosen et al. 2022	94	557	91	504	13.7%	0.92 [0.67, 1.27]	
akupova, Suarez et al. 2021	279	611	722	1645	17.2%	1.07 [0.89, 1.29]	+
anardo, Manghina et al.2020	12	101	26	91	5.6%	0.34 [0.16, 0.72]	
hang, Okeke et al. 2022	17	285	12	85	5.3%	0.39 [0.18, 0.84]	
ubtotal (95% CI)		3688		3942	100.0%	0.79 [0.64, 0.97]	•
otal events	1017		1545				
eterogeneity: Tau ² = 0.06; Chi ² = 22.84, df = 10	(P = 0.01);	I ² = 56%					
est for overall effect: Z = 2.25 (P = 0.02)							
5.2 Moderate quality							
hrzan-Dętkoś, Walczak-Kozłowska et al.2021	48	61	65	78	7.3%	0.74 [0.31, 1.74]	
iiragi, Obata et al.2021	34	339	38	279	13.0%	0.71 [0.43, 1.16]	
ui, Ma et al.2021 (D1)	410	3432	133	925	19.2%	0.81 [0.65, 1.00]	
ui, Ma et al.2021 (VV1)	69	2970	23	802	13.3%	0.81 [0.50, 1.30]	
ayton, Owais et al. 2021	217	305	240	298	15.5%	0.60 [0.41, 0.87]	
ariño-Narvaez, Puertas-Gonzalez et al. 2021	19	82	28	75	9.4%	0.51 [0.25, 1.01]	
ariente, Wissotzky Broder et al.2020	38	123	37	223	12.5%	2.25 [1.34, 3.78]	
uzuki 2020	22	148	19	132	9.9%	1.04 [0.53, 2.02]	-
ubtotal (95% CI)		7460		2812	100.0%	0.84 [0.63, 1.11]	•
otal events	857		583				
eterogeneity: Tau ² = 0.10; Chi ² = 19.92, df = 7 (P = 0.006);	l² = 65%					
est for overall effect: Z = 1.22 (P = 0.22)							
							uun un 1 10 11

FIGURE 5

Subgroup analysis comparing the prevalence of PPDS before and during the COVID-19 pandemic according to study quality.

	Pre-pand	emic	Pande	mic		Odds Ratio	Odds Ratio
Audy or Subgroup	Events	lotal	Events	lotal	weight	M-H, Random, 95% CI	M-H, Random, 95% CI
.b.1 Developed			-				
loekhorst, Muskens et al. 2021	17	250	5	59	3.1%	0.79 [0.28, 2.23]	
hrzan-Dętkos, Walczak-Kozłowska et al.2021	48	61	65	78	4.1%	0.74 [0.31, 1.74]	
liiragi, Obata et al.2021	34	339	38	279	7.1%	0.71 [0.43, 1.16]	
(uipers, Bleijenbergh et al. 2022	106	456	29	148	7.5%	1.24 [0.78, 1.97]	
ayton, Owais et al. 2021	217	305	240	298	8.4%	0.60 [0.41, 0.87]	
lariño-Narvaez, Puertas-Gonzalez et al. 2021	19	82	28	75	5.2%	0.51 [0.25, 1.01]	
ariente, Wissotzky Broder et al.2020	38	123	37	223	6.8%	2.25 [1.34, 3.78]	
erez, Göbel et al. 2021	8	97	11	65	3.5%	0.44 [0.17, 1.17]	
Pietro Madera	43	605	35	295	7.4%	0.57 [0.36, 0.91]	
uertas-Gonzalez, Mariño-Narvaez et al. 2021	25	96	33	116	6.0%	0.89 [0.48, 1.63]	
ade, Sheiner et al. 2020	21	84	81	279	6.5%	0.81 [0.47, 1.42]	
Juzuki 2020	22	148	19	132	5.5%	1.04 [0.53, 2.02]	
Vaschmann, Rosen et al. 2022	94	557	91	504	9.1%	0.92 [0.67, 1.27]	
'akupova, Suarez et al. 2021	279	611	722	1645	10.4%	1.07 [0.89, 1.29]	+
anardo, Manghina et al.2020	12	101	26	91	4.8%	0.34 [0.16, 0.72]	
hang, Okeke et al. 2022	17	285	12	85	4.6%	0.39 [0.18, 0.84]	
Subtotal (95% CI)		4200		4372	100.0%	0.79 [0.64, 0.98]	◆
otal events	1000		1472				
leterogeneity: Tau ² = 0.11; Chi ² = 42.59, df = 15 est for overall effect: Z = 2.13 (P = 0.03)	(P = 0.0002	2); I ² = 65	5%				
.6.2 Developing							
lui, Ma et al.2021 (D1)	410	3432	133	925	54.1%	0.81 [0.65, 1.00]	
lui, Ma et al.2021 (W1)	69	2970	23	802	10.5%	0.81 [0.50, 1.30]	
i, Wang et al. 2022	395	546	500	655	35.5%	0.81 [0.63, 1.05]	-=-
subtotal (95% CI)		6948		2382	100.0%	0.81 [0.69, 0.94]	•
otal events	874		656				
leterogeneity: Tau ² = 0.00; Chi ² = 0.00, df = 2 (F est for overall effect: Z = 2.69 (P = 0.007)	e = 1.00); l ² =	0%					
							0.01 0.1 1 10 100
							Links Dendamia Links Des nondensis

FIGURE 6

Subgroup analysis comparing the prevalence of PPDS before and during the COVID-19 pandemic according to different country types.

Aug of Subgroup 7.1 Europe ekhorst, Muskens et al. 2021 nzan-Dętkoś, Walczak-Kozłowska et al.2021 nińo-Narvaez, Puertas-Gonzalez et al. 2021 nriente, Wissotzky Broder et al.2020 nrez, Göbel et al. 2021 etro Madera ertas-Gonzalez, Mariño-Narvaez et al. 2021 kupova, Suarez et al. 2021	17 48 106 19 38 8 43	250 61 456 82 123 97	5 65 29 28 37	59 78 148 75	6.1% 7.7% 12.2%	0.79 [0.28, 2.23] 0.74 [0.31, 1.74]	
remote rekhorst, Muskens et al. 2021 rizan-Dętkoś, Walczak-Kozłowska et al.2021 riño-Narvaez, Puertas-Gonzalez et al. 2021 rriente, Wissotzky Broder et al.2020 rrez, Göbel et al. 2021 etro Madera ertas-Gonzalez, Mariño-Narvaez et al. 2021 kupova, Suarez et al. 2021	17 48 106 19 38 8 43	250 61 456 82 123 97	5 65 29 28 37	59 78 148 75	6.1% 7.7% 12.2%	0.79 [0.28, 2.23] 0.74 [0.31, 1.74]	
irzan-Dętkoś, Walczak-Kozłowska et al.2021 irzan-Dętkoś, Walczak-Kozłowska et al.2021 irjers, Bleijenbergh et al. 2022 iriño-Narvaez, Puertas-Gonzalez et al. 2021 iriente, Wissotzky Broder et al.2020 irez, Göbel et al. 2021 etro Madera iertas-Gonzalez, Mariño-Narvaez et al. 2021 kupova, Suarez et al. 2021	17 48 106 19 38 8 43	250 61 456 82 123 97	5 65 29 28 37	59 78 148 75	7.7% 12.2%	0.79 [0.28, 2.23] 0.74 [0.31, 1.74]	
irzari-Dekkos, walczak-Kozłowska et al.2021 lipers, Bleijenbergh et al. 2022 iriño-Narvaez, Puertas-Gonzalez et al. 2021 iriente, Wissotzky Broder et al.2020 irez, Göbel et al. 2021 etro Madera iertas-Gonzalez, Mariño-Narvaez et al. 2021 kupova, Suarez et al. 2021	48 106 19 38 8 43	456 82 123 97	29 28 37	78 148 75	12.2%	0.74 [0.31, 1.74]	
upers, bleijenbergn et al. 2022 ariño-Narvaez, Puertas-Gonzalez et al. 2021 rirente, Wissotzky Broder et al.2020 rrez, Göbel et al. 2021 etro Madera etras-Gonzalez, Mariño-Narvaez et al. 2021 kupova, Suarez et al. 2021	106 19 38 8 43	456 82 123 97	29 28 37	148 75	12.2%		
nrno-Narvaez, Puertas-Gonzalez et al. 2021 nriente, Wissotzky Broder et al.2020 nrez, Göbel et al. 2021 etro Madera etras-Gonzalez, Mariño-Narvaez et al. 2021 kupova, Suarez et al. 2021	19 38 8 43	82 123 97	28	75		1.24 [0.78, 1.97]	
rriente, Wissotzky Broder et al.2020 irrez, Göbel et al. 2021 etro Madera ertas-Gonzalez, Mariño-Narvaez et al. 2021 kupova, Suarez et al. 2021	38 8 43	123 97	37		9.3%	0.51 [0.25, 1.01]	
rrez, Göbel et al. 2021 etro Madera iertas-Gonzalez, Mariño-Narvaez et al. 2021 kupova, Suarez et al. 2021	8 43	97		223	11.5%	2.25 [1.34, 3.78]	
etro Madera Iertas-Gonzalez, Mariño-Narvaez et al. 2021 kupova, Suarez et al. 2021	43		11	65	6.6%	0.44 [0.17, 1.17]	
iertas-Gonzalez, Mariño-Narvaez et al. 2021 kupova, Suarez et al. 2021	0.5	605	35	295	12.1%	0.57 [0.36, 0.91]	
kupova, Suarez et al. 2021	25	96	33	116	10.4%	0.89 [0.48, 1.63]	
	279	611	722	1645	15.4%	1.07 [0.89, 1.29]	+
nardo, Manghina et al.2020	12	101	26	91	8.7%	0.34 [0.16, 0.72]	
btotal (95% CI)		2482		2795	100.0%	0.82 [0.59, 1.13]	•
tal events	595		991				
eterogeneity: Tau ² = 0.17; Chi ² = 31.31, df = 9 (I	P = 0.0003)	; I ² = 719	6				
st for overall effect: Z = 1.21 (P = 0.23)							
7.2 Asia							
iragi, Obata et al.2021	34	339	38	279	8.0%	0.71 [0.43, 1.16]	
ui, Ma et al.2021 (D1)	410	3432	133	925	43.9%	0.81 [0.65, 1.00]	
ui, Ma et al.2021 (VV1)	69	2970	23	802	8.5%	0.81 [0.50, 1.30]	
Wang et al. 2022	395	546	500	655	28.8%	0.81 [0.63, 1.05]	
ide, Sheiner et al. 2020	21	84	81	279	6.3%	0.81 [0.47, 1.42]	
izuki 2020	22	148	19	132	4.4%	1.04 [0.53, 2.02]	
btotal (95% CI)		7519		3072	100.0%	0.81 [0.70, 0.93]	◆
tal events	951		794				
eterogeneity: Tau ² = 0.00; Chi ² = 0.83, df = 5 (P	= 0.97); l ² =	0%					
st for overall effect: Z = 2.97 (P = 0.003)							
7 3 North Amorica							
ston Owaie at al. 2021	217	205	240	200	20.2%	0 60 10 41 0 971	
yton, Owars et al. 2021 Sectimental Decension of al. 2022	217	500	240	200	41 00	0.00 [0.41, 0.87]	
aschinann, Rusen et al. 2022	34	207	31	004	41.9%	0.92 [0.07, 1.27]	
ang, Okeke et al. 2022 Istatal (05% CI)	17	200	12	007	100.0%	0.59 [0.16, 0.84]	
tol questo	220	1147	242	00/	100.0%	0.00 [0.42, 1.02]	•
ital events storogonoity: Touã = 0.00: Chiã = 6.70, df = 0.70	328 = 0.06\: 12-	660	343				
st for overall effect: Z = 1.89 (P = 0.06)	= 0.06), 1- =	00%					
							0.01 0.1 1 10 10
							Higher Pandemic Higher Pre-pandemic

Subgroup analysis comparing the prevalence of PPDS before and during the COVID-19 pandemic according to different continents.

(50). However, depressive symptoms that start beyond 4 weeks after delivery can still cause harm and require treatment. Assessment for postpartum depression is still recommended, in clinical practice, within the first 12 months after delivery (51). About 70% of new mothers experience mild depressive symptoms postpartum which usually begins to subside spontaneously within 2 weeks without significant impairment of function or continued psychotic symptoms (46). In this study, we conducted further subgroup analysis according to the postpartum time, and results showed that the prevalence of PPDS within 2 weeks after delivery showed no difference before and during the COVID-19 period, while the prevalence of postpartum depression increased obvious during the COVID-19 pandemic period when detected 2 weeks after delivery (Figure 4). Based on the current research results, the impact of the COVID-19 pandemic on PPDS is more long-lasting and lactating women should be provided with adequate psychological support to reduce the long-term negative effects of this pandemic.

4.3. Subgroups with different study quality

We also evaluated the heterogeneity based on the study quality. Subgroup analysis of these studies with high quality provided further evidence of the negative impact of the pandemic on PPDS, while no significant effect was shown in studies with moderate quality.

4.4. Subgroups with different regions

Our study found an increase of PPDS during the COVID-19 pandemic period in Asia ($I^2 = 0\%$), while studies conducted in Europe and North America showed no significant increase of PPDS prevalence (Figure 7). One recent meta-analysis that found an increased PPDS prevalence during the COVID-19 over the world with high heterogeneity ($I^2 = 95\%$) (21). No further subgroups analysis were conducted in this meta-analysis (21). Furthermore, the high heterogeneity between studies that may negatively affect the accuracy of the result. The robustness of the results from this metaanalysis was controlled by conducting sensitivity analysis. Studies that utilized different screening tools and studies that focused only on mothers of extreme and early preterm infants were excluded to achieve better analysis results (26, 36, 37).

4.5. Subgroups with different country types

Both of the study subgroups that were conducted in developing and developed countries showed a significant negative impact from the COVID-19 to the prevalence of postpartum depression (Figure 6). The number of studies in developing subgroups was limited, further evidence is needed to examine potential differences in these subgroups. In addition to the factors mentioned above, strict isolation measures, level of education, economy, and social support, etc. can also have a negative impact on the mental health of the postpartum women (52, 53). Due to the limitations of the included studies, we were unable to further analyze these possible influencing factors. Multi-center high-quality research with large-sample sizes and perhaps, longitudinal research methods should be considered for future studies.

5. Strengths and limitations

This systematic review and meta-analysis compared the prevalence of PPDS before versus during the COVID-19 pandemic and explored possible influencing factors on postpartum depression from study characteristics and regions. Statistical analysis was carried out within different subgroups to demonstrate the possible negative effects from the COVID-19 pandemic on PPDS. However, it is undeniable that this research has some limitations. Firstly, many of the included studies collected their relevant data using internet surveys due to the quarantine policies during the pandemic which may have given rise to selection and decision biases. Secondly, some of the included studies did not depict the severity of the epidemic situation and the isolation measures during the study period which are all important influencing factors to mental health. Lastly, the limited number and the high heterogeneity of included articles also potentially affected the accuracy of the results.

6. Conclusion

This meta-analysis compared the prevalence of PPDS before vs. during the COVID-19 pandemic. Subgroup analyses were conducted to further examine the possible influencing factors. The results of subgroup analysis showed that the COVID-19 pandemic was associated with an increased prevalence of PPDS, especially in long-term follow-up studies (>2 weeks), in studies with high possibility of PPDS (EPDS \geq 13) and in studies from Asia. Therefore, policymakers and health planners should give high priority to the mental health of this vulnerable group during a global health crisis and develop better support and assurance measures to deal with the impact of a pandemic on postpartum women.

Author contributions

XZh, CW, BA, FB, and MV designed the review. XZh and CW contributed to conception and design of the study, data acquisition, and analysis and interpretation of data. XZh participated in writing the first draft of the paper. TL, BA, and FB revised critically for important intellectual content and gave final approval of the version to be published. All authors contributed to the intellectual content, read, and approved the final manuscript.

Acknowledgments

The authors wish to thank Thomas Vandendriessche and Krizia Tuand, the biomedical reference librarians of the KU Leuven Libraries–2Bergen—Learning Center Désiré Collen (Leuven, Belgium), for their help in conducting the systematic literature search.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fpubh.2023. 1102618/full#supplementary-material

SUPPLEMENTARY IMAGE 1

Meta-influence analyses of the included studies before (A) and after (B) the apparently deviated study was deleted.

References

1. Liang P, Wang Y, Shi S, Liu Y, Xiong R. Prevalence and factors associated with postpartum depression during the COVID-19 pandemic among women in Guangzhou, China: a cross-sectional study. *BMC Psychiat.* (2020) 20:1–8. doi: 10.1186/s12888-020-02969-3

2. Yang M, Yue W, Han X, Hu C, Sun X, Luo J. Postpartum care indications and methodological quality: a systematic review of guidelines. *J Public Health.* (2021) 2021:1–15. doi: 10.1007/s10389-021-01629-4

3. Ganesan B, Jumaily A, Fong K, Prasad P, Meena S, Tong R, et al. Impact of coronavirus disease (2019). (COVID-19) outbreak quarantine, isolation, and lockdown policies on mental health and suicide. *Front Psychiatry.* (2021) 12:565190. doi: 10.3389/fpsyt.2021.565190

4. Depression P, Causes AT. Heterogeneity of postpartum depression: a latent class analysis. *Lancet Psychiat.* (2015) 2:59–67. doi: 10.1016/S2215-0366(14)00055-8

5. Fatemeh A, Mehran Z. Effect of postpartum depression on women's mental and physical health four years after childbirth. *East Mediterr Health* J. (2018) 24:1002–9. doi: 10.26719/2018.24.10.1002

6. Hahn-Holbrook J, Cornwell-Hinrichs T, Anaya I. Economic and health predictors of national postpartum depression prevalence: a systematic review, meta-analysis, and meta-regression of 291 studies from 56 countries. *Front Psychiatry.* (2017) 8:248. doi: 10.3389/fpsyt.2017.00248

7. Shorey S, Chee CYI, Ng ED, Chan YH, Tam WWS, Chong YS. Prevalence and incidence of postpartum depression among healthy mothers: a systematic review and meta-analysis. *J Psychiatr Res.* (2018) 104:235–48. doi: 10.1016/j.jpsychires.2018.08.001

8. Anokye R, Acheampong E, Budu-Ainooson A, Obeng EI, Akwasi AG. Prevalence of postpartum depression and interventions utilized for its management. *Ann Gen Psychiatry.* (2018) 17:18. doi: 10.1186/s12991-018-0188-0

9. Lindahl V, Pearson JL, Colpe L. Prevalence of suicidality during pregnancy and the postpartum. Arch Womens Ment Health. (2005) 8:77–87. doi: 10.1007/s00737-005-0080-1

10. McPeak KE, Sandrock D, Spector ND, Pattishall AE. Important determinants of newborn health: postpartum depression, teen parenting, and breast-feeding. *Curr Opin Pediatr*. (2015) 27:138–44. doi: 10.1097/MOP.00000000000185

11. Usmani S, Greca E, Javed S, Sharath M, Sarfraz Z, Sarfraz A, et al. Risk factors for postpartum depression during covid-19 pandemic: a systematic literature review. *J Primary Care Community Health.* (2021) 12:21501327211059348. doi:10.1177/21501327211059348

12. Suzuki S. Psychological status of postpartum women under the COVID-19 pandemic in Japan. J Matern Fetal Neonatal Med. (2020) 2020:1–3. doi: 10.1080/14767058.2020.1763949

13. Pariente G, Broder OW, Sheiner E, Battat TL, Mazor E, Salem SY, et al. Risk for probable post-partum depression among women during the COVID-19 pandemic. *Arch Womens Ment Health*. (2020) 23:767–73. doi: 10.1007/s00737-020-01075-3

14. Kuipers YJ, Bleijenbergh R, Van den Branden L, van Gils Y, Rimaux S, Brosens C, et al. Psychological health of pregnant and postpartum women before and during the COVID-19 Pandemic. *PLoS ONE.* (2022) 17:e0267042. doi: 10.1371/journal.pone.0267042

15. Zanardo V, Manghina V, Giliberti L, Vettore M, Severino L, Straface G. Psychological impact of COVID-19 quarantine measures in northeastern Italy on mothers in the immediate postpartum period. *Int J Gynaecol Obstet.* (2020) 150:184–8. doi: 10.1002/ijgo.13249

16. Zhang CXW, Okeke JC, Levitan RD, Murphy KE, Foshay K, Lye SJ, et al. Evaluating depression and anxiety throughout pregnancy and after birth: impact of the COVID-19 pandemic. *Am J Obstet Gynecol MFM.* (2022) 4:100605. doi: 10.1016/j.ajogmf.2022.100605

17. Perez A, Göbel A, Stuhrmann LY, Schepanski S, Singer D, Bindt C, et al. Born under COVID-19 pandemic conditions: infant regulatory problems and maternal mental health at 7 months postpartum. *Front Psychol.* (2021) 12:805543. doi: 10.3389/fpsyg.2021.805543

18. Yan H, Ding Y, Guo W. Mental Health of Pregnant and Postpartum Women During the Coronavirus Disease 2019. Pandemic: a systematic review and meta-analysis. *Front Psychol.* (2020) 11:617001. doi: 10.3389/fpsyg.2020.617001

19. Shorey SY, Ng ED, Chee CYI. Anxiety and depressive symptoms of women in the perinatal period during the COVID-19 pandemic: A systematic review and meta-analysis. *Scand J Public Health.* (2021) 49:730–40. doi: 10.1177/14034948211011793

20. Hessami K, Romanelli C, Chiurazzi M, Cozzilin M. COVID-19 pandemic and maternal mental health: a systematic review and meta-analysis. *J Matern Fetal Neonatal Med.* (2022) 35:4014–21. doi: 10.1080/14767058.2020.1843155

21. Lin C, Chen B, Yang Y, Li Q, Wang Q, Wang M, et al. Association between depressive symptoms in the postpartum period and COVID-19: a meta-analysis. *J Affect Disord*. (2022) 320:247–53. doi: 10.1016/j.jad.2022.09.129

22. Stroup DF, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting meta-analysis of observational studies in epidemiology (MOOSE) group. *Jama*. (2000) 283:2008–12. doi: 10.1001/jama.283.15.2008

23. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med.* (2009) 151:W65–94. doi: 10.7326/0003-4819-151-4-200908180-00136

24. Chrzan-Detkoś M, Walczak-Kozłowska T, Lipowska M. The need for additional mental health support for women in the postpartum period in the times of epidemic crisis. *BMC Pregnancy Childbirth.* (2021) 21:114. doi: 10.1186/s12884-021-03544-8

25. Boekhorst MGBM, Muskens L, Hulsbosch LP, Van Deun K, Bergink V, Pop VJM, et al. The COVID-19 outbreak increases maternal stress during pregnancy, but not the risk for postpartum depression. *Arch Womens Ment Health.* (2021) 24:1037–43. doi: 10.1007/s00737-021-01104-9

26. Eberhard-Gran M, Engelsen LY, Al-Zirqi I, Vangen S. Depressive symptoms and experiences of birthing mothers during COVID-19 pandemic. *Tidsskr Nor Laegeforen.* (2022) 142:3. doi: 10.4045/tidsskr.21.0450

27. Hiiragi K, Obata S, Misumi T, Miyagi E, Aoki S. Psychological stress associated with the COVID-19 pandemic in postpartum women in Yokohama, Japan. *J Obstet Gynaecol Res.* (2021) 47:2126–30. doi: 10.1111/jog.14776

28. Hui PW, Ma G, Seto MTY, Cheung KW. Effect of COVID-19 on delivery plans and postnatal depression scores of pregnant women. *Hong Kong Med J.* (2021) 27:113–7. doi: 10.12809/hkmj208774

29. Layton H, Owais S, Savoy C, Lieshout R. Depression, anxiety, and motherinfant bonding in women seeking treatment for postpartum depression before and during the COVID-19 pandemic. *J Clin Psychiatry.* (2021) 82:4. doi: 10.4088/JCP.21m 13874

30. Li S, Wang L, Wang W, Hou S, Xie C, Zeng M, et al. Comparison of sleep quality among puerperal women before and during the COVID-19

pandemic: a cross-sectional survey in Lanzhou, China. Sleep Breath. (2022) 2022:1–8. doi: 10.1007/s11325-021-02553-3

31. Loret de Mola C, Silva TS, Carpena MX, Ponte B, Blumenberg C, Martis R, et al. Maternal mental health before and during the COVID-19 pandemic in the (2019). Rio Grande birth cohort. Braz J Psychiatry. (2021). 43(4):402-406. doi: 10.1590/1516-4446-2020-1673

32. Mariño-Narvaez C, Puertas-Gonzalez JA, Romero-Gonzalez B, Peralta-Ramirez MI. Giving birth during the COVID-19 pandemic: the impact on birth satisfaction and postpartum depression. *Int J Gynaecol Obstet*. (2021) 153:83–8. doi: 10.1002/ijgo.13565

33. Madera P, Romagnolo C, Zanetti S, Maso FD, Turro M, De Marco C. Effects of the COVID-19 pandemic on postpartum depression: A retrospective case-control study on A significant sample of mothers in northern Italy. *J Prenat Perinat Psychol Health*. (2021) 35:30–8. Available online at: https://www.proquest.com/scholarly-journals/effects-covid-19-pandemic-on-postpartum/docview/258224806/se-2

34. Puertas-Gonzalez JA, Mariño-Narvaez C, Romero-Gonzalez B, Peralta-Ramirez MI. Giving birth during a pandemic: From elation to psychopathology. *Int J Gynaecol Obstet.* (2021) 155:466–74. doi: 10.1002/ijgo.13803

35. Sade S, Sheiner E, Wainstock T, Hermon N, Salem SY, Kosef T, et al. Risk for depressive symptoms among hospitalized women in high-risk pregnancy units during the COVID-19 pandemic. *J Clin Med.* (2020) 9:8. doi: 10.3390/jcm9082449

36. Sudhinaraset M, Landrian A, Mboya J, Golub G. The economic toll of COVID-19: A cohort study of prevalence and economic factors associated with postpartum depression in Kenya. *Int J Gynaecol Obstet.* (2022) 158:110–15. doi: 10.1002/ijgo.14142

37. Vatcheva T, Mostaert A, Van Ingelgem V, Henrion E, Legros L. Impact of COVID-19 pandemic on postpartum depression among mothers of extreme and early preterm infants. *Int J Gynaecol Obstet*. (2021) 155:490–5. doi: 10.1002/ijgo.13859

38. Waschmann M, Rosen K, Gievers L, Hildebrand A, Laird A, Khaki S. Evaluating the impact of the COVID-19 pandemic on postpartum depression. J Womens Health (Larchmt). (2022) 31:772-8. doi: 10.1089/jwh.2021.0428

39. Yakupova V, Suarez A, Kharchenko A. Birth experience, postpartum PTSD and depression before and during the pandemic of COVID-19 in Russia. *Int J Environ Res Public Health.* (2021) 19:335. doi: 10.3390/ijerph19010335

40. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. *Eur J Epidemiol.* (2010) 25:603–5. doi: 10.1007/s10654-010-9491-z

41. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557

42. DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. *Contemp Clin Trials*. (2007) 28:105–14. doi: 10.1016/j.cct.2006.04.004

43. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics.* (1994) 50:1088–101. doi: 10.2307/2533446

44. Liu X, Gao W, Yan H. Measuring and decomposing the inequality of maternal health services utilization in western rural China. *BMC Health Serv Res.* (2014) 14:102. doi: 10.1186/1472-6963-14-102

45. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh postnatal depression scale. *Br J Psychiatry*. (1987) 150:782–6. doi: 10.1192/bjp.150.6.782

46. Wisner KL, Parry BL, Piontek CM. Postpartum depression. N Engl J Med. (2002) 347:194–9. doi: 10.1056/NEJMcp011542

47. Henshaw C. Mood disturbance in the early puerperium: a review. Arch Womens Ment Health. (2003) 6:s33–42. doi: 10.1007/s00737-003-0004-x

48. Levis B, Negeri Z, Sun Y, Benedetti A, Thombs BD, Group DSD. Accuracy of the Edinburgh Postnatal Depression Scale (EPDS) for screening to detect major depression among pregnant and postpartum women: systematic review and meta-analysis of individual participant data. *BMJ*. (2020) 371:m4022. doi: 10.1136/bmj.m4022

49. Okano T, Nomura J, Kumar R, Kaneko E, Tamaki R, Hanafusa I, et al. An epidemiological and clinical investigation of postpartum psychiatric illness in Japanese mothers. *J Affect Disord.* (1998) 48:233–40. doi: 10.1016/S0165-0327(97)00158-4

50. Battle DE. Diagnostic and statistical manual of mental disorders (DSM). *Codas.* (2013) 25:191–2. doi: 10.1590/s2317-17822013000200017

51. Stewart DE, Vigod S. Postpartum depression. N Engl J Med. (2016) 375:2177–86. doi: 10.1056/NEJMcp1607649

52. Silverman ME, Burgos L, Rodriguez ZI, Afzal O, Kalishman A, Callipari F, et al. Postpartum mood among universally screened high and low socioeconomic status patients during COVID-19 social restrictions in New York City. *Sci Rep.* (2020) 10:22380. doi: 10.1038/s41598-020-79564-9

53. VidhiChaudhary, Puri M, Kukreti P, Chhapola V, Kanwar D, Tumpati A, et al. Postpartum depression in COVID-19 risk-stratified hospital zones: a cross-sectional study from India. J Affect Disord Rep. (2021) 6:100269. doi: 10.1016/j.jadr.2021.100269